Fatty Liver Diseases: A Public Health Concern, But Market Opportunity
A new epidemiological analysis suggests the increasing number of patients from across the globe with some form of non-alcoholic fatty liver disease promises an effective therapy would be a welcome addition to the armamentarium of liver disease specialists.
You may also be interested in...
The numerous different targets of investigational drugs for the treatment of NASH suggest the jury is still out on which mechanism of action is most likely to prove effective against the condition. Ireland’s Afimmune is the latest company wanting to advance an investigational drug for the disorder into late-stage clinical studies.
OptumRx, Harvard Pilgrim watching closely as Intercept’s Ocaliva nears market entry with claim for primary biliary cholangitis; use restrictions against off-label use in NASH are likely.
The UK’s Vectura plc is gaining value from its back catalog of novel compounds through licensing its pan-JAK inhibitor, VR588, to a US start-up, the venture capital-backed Kinaset Therapeutics.